The neurologic presentation of XXXX . A review.

@entity1158 @entity6220 @entity2884 @entity12513 @entity54692 @entity1333 @entity6435 @entity14033 @entity262 @entity1252 @entity709 @entity71082 @entity751 @entity230
Most @entity751 can affect the central nervous system (CNS). In the vast majority of cases, however, the @entity262 is present at the time of first CNS manifestations. Certain of these diseases, including @entity1252 , @entity71082 , @entity709 , @entity14033 and @entity2884 can present with CNS findings in the absence of any peripheral evidence of the underlying process. The CNS presentations of these and the other @entity751 which may affect the CNS are discussed. Isolated @entity12513 may be due to @entity54692 ( @entity54692 ) or delayed contralateral @entity1158 following HZO. These are distinct clinical entities which can be differentiated by clinical and angiographic findings. The former is often severe and diffuse in nature, whereas the latter is usually milder and more focal. There are few if any peripheral findings in either syndrome. The cause of @entity54692 is unknown, but the @entity1158 following HZO is clearly due to a virus-induced @entity1333 spread from the overlying Gasserian nucleus; the history of preceding herpes @entity6435 strongly suggests the diagnosis. The collected evidence suggests that an aggressive evaluation, including meningeal biopsy, and early therapy with @entity230 (and perhaps cytotoxic agents) can alter the prognosis in @entity54692 . It is not clear that @entity1158 following HZO requires treatment. @entity54692 and HZO-associated CNS damage should be considered in the differential diagnosis of isolated @entity6220 in the absence of history, signs, or laboratory abnormalities suggestive of @entity262 .
